Scientists hunt for early warning signs of kidney failure in rare genetic diseases
NCT ID NCT04874909
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study collected blood and urine samples from 240 people with ciliopathies—rare genetic disorders that often lead to kidney failure. Researchers analyzed these samples to find biological markers that could predict how the disease will progress. The goal is to develop a test that helps doctors identify patients at highest risk for kidney problems, allowing for earlier and more personalized care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a test that predicts which ciliopathy patients will develop kidney failure, enabling earlier monitoring and care.
- What could go wrong
- This is an observational study, not a treatment trial. The findings may not lead to a usable test, and results may not apply to all ciliopathy types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BARDET BIEDL SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker-Enfants Malades
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a drug that targets the brain's hunger pathway help people with Bardet-Biedl syndrome?
- New registry aims to unlock secrets of rare Kidney-Liver diseases
- Weight loss jab shows promise for rare obesity syndrome
- Thousands join fight against blindness by sharing their stories
- 150 patients tracked to map rare kidney disease's long-term damage
- Scientists hunt for drug targets in rare kidney disorder